LENZ Overview

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

Wall Street analysts forecast LENZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LENZ is57.50 USD with a low forecast of 52.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

LENZ Therapeutics Inc revenue for the last quarter amounts to 12.50M USD, decreased

LENZ Therapeutics Inc. EPS for the last quarter amounts to -0.59 USD, increased 55.26

LENZ Therapeutics Inc (LENZ) has 42 emplpoyees as of March 03 2026.

Today LENZ has the market capitalization of 428.05M USD.